Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Martin Shkreli violated lifetime pharma industry ban, FTC and states say

14 October 2026 · By · Wire by Fusion42

Published

14 October 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 14 October 2026 · Fusion42 review

Martin Shkreli has violated a lifetime ban from the pharmaceutical industry by trading stocks and discussing companies in the sector, prompting federal and state regulators to seek contempt proceedings and fines against him.

This Wire brief sits within Fusion42's coverage of Health, and 8 sources have reported it between 13 Oct 2026 and 14 Oct 2026.

◆ ◆ The Wire takeaway

You face increased regulatory scrutiny if you try to bypass industry bans through stock trading or public commentary. This enforcement signals tighter controls and reduced tolerance for skirted compliance in pharma.

◆ Coverage

8 sources · first reported 13 Oct 2026 · latest 14 Oct 2026

◆ Topics

Healthpharma-banregulatory-enforcementstock-tradinghealthlegal